Herbert Smith Freehills Kramer (HSF Kramer) and O’Melveny advised on Medcaptain Medical Technology’s Hong Kong IPO and listing.

Shenzhen Medcaptain Medical Technology Co., Ltd. (2041.HK) completed its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange. Medcaptain is a global integrated medical device provider with three major brands—Medcaptain, Penlon and Vedkang Medical—and products spanning life support, minimally invasive intervention and in vitro diagnostics, reaching over 140 countries and regions worldwide.

Medcaptain’s diversified product portfolio has reached over 6,000 hospitals, including approximately 90% of Grade 3A hospitals in China. According to China Insights Consultancy, Medcaptain’s innovative and high-quality medical products, along with its extensive coverage across clinical departments, position it as one of the most comprehensive medical device companies in China.

Herbert Smith Freehills Kramer advised Medcaptain on the listing.

Partners Matt Emsley, Stanley Xie and Jin Kong led a cross-office team, assisted by Jaime Fong, Scarlet Feng, Cyrus Wong, Vera Chen, Francis Wang, Renee Fung, Maxine Law and Huaien Tang.

O’Melveny represented joint sponsors Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited and the underwriters.

The team was led by partners Ke Geng, Ke Zhu and Vincent Wang. The core team members included counsel Jerry Gao, Edward Poon and Xiaoqiu Huang, associate Estella Zhang, legal manager Simon Xu, legal consultant Audrey Zhan, and legal manager Belinda Zhu. Legal consultant Sienna Wang, and legal consultant intern Iris Mu and Andrew Yang also made valuable contributions.